In the involution phase, an<unk>  finally begins to diminish in size. While<unk> s were previously thought to improve by about 10% each year, newer evidence suggests that maximal improvement and involution is typically reached by 3.5 years of age. Most<unk> s resolve by age 10, but in some patients, the<unk>  does not completely resolve. Residual redness may be noted and can be improved with laser therapy, most commonly PDL. Ablative fractional resurfacing may be considered for textural skin changes.<unk> s, especially those that have gotten very large during the growth phase, may leave behind stretched skin or fibrofatty tissue that may be disfiguring or require future surgical correction. Areas of prior ulceration may leave behind permanent scarring. Additional long-term sequelae stem from the identification of extracutaneous manifestations in association with the<unk> . For example, a patient with a large facial<unk>  who is found to meet criteria for PHACE syndrome will require potentially ongoing neurologic, cardiac, and/or ophthalmologic monitoring. In cases of<unk> s that compromise of vital structures, symptoms may improve with involution of the<unk> . For example, respiratory distress would improve with involution of a space-occupying<unk>  involving the airway and high-output heart failure may lessen with involution of a hepatic<unk>  and ultimately treatment may be tapered or discontinued. In other cases, such as an untreated eyelid<unk> , resultant amblyopia does not improve with involution of the cutaneous lesion. For these reasons, infants with<unk> s should be evaluated by an appropriate clinician during the early proliferative phase so that risk monitoring and treatment be individualized and outcomes can be optimized.
Infantile hemangioma
Chorangioma
Lymphohemangioma
Spider angioma
Boomerang dysplasia
Cherry angioma
Tufted angioma
Angiokeratoma